A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies

Gynecologic Oncology

Volumn 91, Issue 2, 2003, Pages 293-298

  Matulonis, U ^a   Campos, S ^a   Duska, L ^b   Fuller, A ^b   Berkowitz, R ^c   Gore, S ^b   Roche, M ^b   Colella, T ^a   Lee, H ^a   Seiden, M V ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adriamycin; Cisplatin; Gemcitabine; Neupogen treatment; Ovarian cancer; Paclitaxel; Topotecan

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; TOPOTECAN;

ABSCESS; ADULT; ADVANCED CANCER; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CYTOREDUCTIVE SURGERY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; FATIGUE; FEMALE; FEMALE GENITAL TRACT CANCER; FEVER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; HYPOTENSION; INFECTION; INTESTINE OBSTRUCTION; KIDNEY DISEASE; LUNG TOXICITY; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; MUELLERIAN DUCT; MYALGIA; NAUSEA; NEPHROLITHIASIS; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PAPILLARY CARCINOMA; PELVIS ABSCESS; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SECOND LOOK SURGERY; THROMBOCYTOPENIA; TOXICITY; TRANSIENT ISCHEMIC ATTACK; UTERINE TUBE CARCINOMA; VOMITING;

EID: 0242383981     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00496-7     Document Type: Article

References (24)

1. Cannistra S.A. Cancer of the ovary. N Engl J Med. 329:1993;1550-1559.
2. Nejit J.P., Engelholm S.A., Tuxen M.K., Sorensen P.G., Hansen M., Sessa C., DeSwart C.A., Hirsch F.R., Lund B., van Houwelingen H.C. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 17:2000;3084-3092.
3. Ozols R.F. Paclitaxel plus carboplatin in the treatment of ovarian cancer. Semin Oncol. 26:(1 suppl 2):1999;84-89. [Review].
4. Friedlander M., Millward M.J., Bell D. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol. 9:(12):1998;1343-1345.
5. Shapiro J.D., Millward M.J., Rischin D. Activity of gemcitabine in patients with advanced ovarian cancer responses seen following platinum and paclitaxel. Gynecol Oncol. 63:1996;89-93.
6. McGuire W.P., Blessing J.A., Bookman M.A., Lentz S.S., Dunton C.J. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma a Gynecologic Oncology Group Study. J Clin Oncol. 18:(5):2000;1062-1067.
7. Creemers G.J., Bolis G., Gore M., Scarfone G., Lacave A.J., Guastalla J.P., Despax R., Favalli G., Kreinberg R., Van Belle S., Hudson I., Verweij J., Ten Bokkel Huinink W.W. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer results of a large European phase II study. J Clin Oncol. 14:(12):1996;3056-3061.
8. Bergman A.M., Ruiz van Haperen V.W.T., Veerman G., Kuiper C.M., Peters G.J. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res. 2:1996;521-530.
9. Kroep J.R., Peters G.J., van Moorsel C.J., Catik A., Vermorken J.B., Pinedo H.M., van Groeningen C.J. Gemcitabine-cisplatin a schedule finding study. Ann Oncol. 10:1999;1503-1510.
10. Eder J.P., Chan V., Wong J., Wong Y.W., Ara G., Northey D., Rizvi N., Teicher B.A. Sequence effects of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo. Cancer Chemother Pharmacol. 42:1998;327-335.
11. Gupta E., Toppmeyer D., Zamek R., Much J., Ibrahim N., Goodin S., Kane M., Aisner J., Li X., Haluska P., Meidna M., Corfield A., Vyas V., Natelson E., Giovanella B., Saleem A., Rubin E. Clinical evaluation of sequential topoisomerase targeting in treatment of advanced malignancy. Cancer Therapeutics. 1:1998;292-301.
12. Seiden M.V., Ng S.W., Supko J.G., Ryan D.P., Clark J.W., Lynch T., Huang K.C., Kwiatkowski D., Skarin A., Eder J.P. Jr. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. Clin Cancer Res. 8:(3):2002;691-697.
13. Surgical staging manual, Gynecology Oncology Group.
14. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., Clarke-Pearson D.L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1996;1-6.
15. Alberts D.S., Green S., Hannigan E.V., O'Toole R., Stock-Novack D., Anderson P., Surwit E.A., Malvlya V.K., Nahhas W.A., Jolles C.J. Improved therapeutic index of carboplatinum plus cyclophosphamide versus cisplatin plus cyclophosphamide final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol. 10:1992;706-717.
16. Conte P.F., Bruzzone M., Carnino F., et al. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide a randomized trial in stage III-IV epithelial ovarian carcinoma. J Clin Oncol. 9:1991;658-663.
17. Louie K.G., Ozols R.F., Meyers C.E., Ostchega Y., Jenkins J., Howser D., Young R.C. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. J Clin Oncol. 4:1986;1579-1585.
18. Sutton G.P., Stehman F.B., Einhorn L.H., Roth L.M., Blessing J.A., Ehrlich C.E. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol. 7:1989;223-229.
19. Kohn E.C., Sarosy G.A., Davis P., et al. A phase I/II study of dose-intensive paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer. Gynecol Oncol. 62:1996;181-191.
20. Hoskins P., Eisenhauer E., Vergote I., Dubuc-Lissoir J., Fisher B., Grimshaw R., Oza A., Plante M., Stuart G., Vermorken J. Phase II feasibility study of sequentila couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer a National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol. 18:2000;4038-4044.
21. Gordon A.N., Hancock K.C., Matthews C.M., Messing M., Stringer C.A., Doherty M.G., Teneriello M. Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer. Gynecol Oncol. 85:2002;129-135.
22. Thigpen T. The role of gemcitabine-based doublets in the management of ovarian carcinoma. Semin Oncol. 29:(1 suppl 1):2002;11-16.
23. du Bois A., Luck H.J., Pfisterer J., Schroeder W., Blohmer J.U., Kimmig R., Moebus V., Quaas J. Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer - a dose-finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group. Ann Oncol. 12:2002;115-120.
24. Bookman M.A. Developmental chemotherapy in advanced ovarian cancer incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182). Semin Oncol. 29:(1 suppl 1):2002;20-31.